Is there an industry standard for qualifying shipping lanes for CGT clinical development products? I am currently working with a phase 1 GMP AAV product and would appreciate guidance on US regulatory and/or quality requirements involving shipping qualification studies to and from CDMOs and clinical sites. What development stage is becoming standard practice to initiate shipping qualification studies? Are there additional requirements for CGT AAV products that I need to be aware of ?